利培酮治疗精神分裂症合并慢性肾功能不全氮质血症期的疗效观察

目的探讨利培酮治疗精神分裂症合并慢性。肾功能不全氮质血症期的疗效与安全性。方法将34例精神分裂症合并慢性。肾功能不全氮质血症期的患者设为研究组，随机抽取同期入院的精神分裂症患者34例设为对照组，两组予以利培酮片口服，疗程均为6周。采用阳性和阴性症状量表（PANSS）、治疗中需处理的不良反应症状量表（TESS），在治疗前后分别评定疗效及不良反应。在治疗第6周末评定血清肌酐（Scr）、血尿素氮（BUN）、血钾、血红蛋白的结果。结果两组在治疗各个时点PANSS总分、阳性症状分、阴性症状分及一般精神病理分均明显下降，与治疗前比较差异均有统计学意义（P〈0．05或P〈0．01）。两组在治疗各个时点的PANSS总分和PANSS减分率比较差异均无统计学意义（P〉0．05）。研究组总有效率为76．47％，与对照组的82．35％比较，差异无统计学意义（P〉0．05）。在治疗后第6周末研究组的肾功能、血钾、血红蛋白的结果与治疗前比较差异均无统计学意义（P〉0．05）。两组TESS总分在治疗后第2、4、6周差异均无统计学意义（P〉0．05）。研究组和对照组不良反应发生率分别为55．88％和50．00％，差异无统计学意义（P〉0．05）。结论利培酮治疗精神分裂症合并慢性肾功能不全氮质血症期的疗效与利培酮治疗精神分裂症的疗效相当，不良反应均轻微，未加重慢性肾功能不全氮质血症期患者的肾功能损害。

Observation of curative effect on Risperidone in the treatment of schizophrenia associated with chronic renal insufficiency during azotemia

Objective To explore the efficacy and safety of Risperidone in the treatment of schizophrenia associated with chronic renal insufficiency during azotemia. Methods 34 cases of patients with schizophrenia associated with chronic renal insufficiency of azotemia were taken as study group. 34 cases were as control group who were randomly selected from the same period in hospitalized schizophrenia patients, both groups were given Rispe.Sdone Tablets, con- tinuous treatment for six weeks. Efficacy and adverse events were assessed with the positive and negative symptom scale （PANSS） and treatment emergent symptom scale （TESS） before and after treatment. Assessment of renal function, serum potassium, hemoglobin results in the sixth week of treatment. Results PANSS total scores and positive symptoms points and negative symptoms and general psychopathology scores of the two groups at each time point in the treatment were significantly decreased, the differences were statistically significant （P 〈 0.05 or P 〈 0.01）. The two groups had no statistically significant difference in the treatment of various time points PANSS total score and PANSS reduction rate （P 〉 0.05）. The research group total effective rate was 76.47% and 82.35% of the control group, there was no sta- tistically significant difference （P 〉 0.05）. In the 6th weekend, the renal function, serum potassium, hemoglohin of study group after treatment were compared with before treatment, differences were not statistically significant （P 〉 0.05）. TESS score in two groups after treatment for 4 and 6 Weeks, the difference was not statistically significant （P 〉 0.05）. In the study group and the control group, the incidence of adverse reactions were 55.88% aml 50.00%, the differeme was not statistically significant （P 〉 0.05）. Conclusion Efficacy of Risperidone in the treatment of schizophre- nia associated with chronic renal insufficiency of azotemia and Risperidone in the treatment of sc, hizophrenia in the same efficacy, adverse reactions are mihl, Risperidone does not aggravate impaired renal function of chronic renal in- sufficiency during azotemia.